To further investigate the scheduling and dose-/exposure-related anti-tumor activity of RG7116 and target modulation of HER3, an extended dosing study was performed (seven-weekly doses beginning on Day 18 after tumor implantation—study FaDu_008; Fig. 3a). The gene discussed is ERBB3; the disease is neoplasm.